Tryptamine Therapeutics Ltd. is gearing up to enter the clinic with lead compound TRP-8803, an intravenous-infused psilocybin therapy, in patients with binge eating disorder in conjunction with psychotherapy.

After dropping development in December of its lead program, Spruce Biosciences Inc. has found new life by acquiring a BLA-ready enzyme replacement therapy for the rare genetic neurodegenerative disease Sanfilippo syndrome type B. If approved, the therapy, tralesinidase alfa, could bring Spruce a priority review voucher.

Gilgamesh Pharmaceuticals Inc. has identified phenalkylamine compounds acting as 5-HT2A receptor agonists reported to be useful for the treatment of psychiatric disorders.

Astrogen Co. Ltd. has synthesized prodrugs of 4-hydroxy atomoxetine reported to be useful for the treatment of aphasia, apraxia, attention deficit hyperactivity disorder, cognitive disorders, Alzheimer’s disease, Parkinson’s disease and ischemic stroke.

The etiology of epilepsy, as well as its pathology, still remains evasive. The role that FK506-binding protein 51 (FKBP51) might play in this disease was investigated in a murine model of kainic acid-induced excitotoxic brain injury.

Praetego Inc. and University of California San Diego scientists reported preclinical results for the new small-molecule amadorin PTG-630, a brain-penetrant drug candidate that inhibits the formation of advanced glycation end-products (AGEs).